Literature DB >> 30592782

A histopathologic schema to quantify the burden of cardiac amyloidosis: Relationship with survival and echocardiographic parameters.

Priya Mehta1, David B Chapel1, Neha Goyal1, Dong Bo Yu1, Victor Mor-Avi1, Akhil Narang1, Karima Addetia1, Nitasha Sarswat1, Roberto M Lang1, Aliya N Husain2, Amit R Patel1,3.   

Abstract

BACKGROUND: Despite routine use of echocardiographic parameters to evaluate the severity of cardiac amyloidosis (CA), this methodology has not been well validated. We developed a histopathologic schema for quantifying CA burden and evaluated its relationship with clinical outcomes. Additionally, echocardiographic parameters were tested as potential noninvasive indices of CA burden.
METHODS: We retrospectively studied 59 patients with CA (17 light chain, 42 transthyretin) who underwent endomyocardial biopsies. Light microscopy with staining was used to categorize CA burden as mild-to-moderate (<50%) or high (≥50%). Kaplan-Meier survival analysis was performed for the two groups. In 34 patients with good-quality echocardiograms, we measured left ventricular volumes, ejection fraction (EF), interventricular septal thickness (IVSt), posterior wall thickness (PWt), LV mass, lateral e'-velocity, and global longitudinal strain (GLS). These parameters were compared between the two groups.
RESULTS: Thirty-five patients had mild-to-moderate and 24 severe amyloid burden. Kaplan-Meier curves demonstrated a trend toward worse mortality with high CA burden, which was more common and associated with higher mortality specifically in transthyretin-type patients. Echocardiography-derived IVSt, PWt, and LV mass were directly related to CA burden, while LV EF, e'-velocity, and GLS magnitude were inversely related to CA burden.
CONCLUSIONS: Our findings provided a signal that CA burden is a clinically important entity with potentially valuable prognostic information. Echocardiographic parameters of LV anatomy and function correlate with histopathologic burden of CA, which is inversely related to survival. Further studies are needed to determine whether these parameters could be used as imaging biomarkers of treatment-related changes in CA burden.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  cardiac amyloidosis; echocardiography; endomyocardial biopsy; longitudinal strain

Mesh:

Year:  2018        PMID: 30592782      PMCID: PMC8240650          DOI: 10.1111/echo.14245

Source DB:  PubMed          Journal:  Echocardiography        ISSN: 0742-2822            Impact factor:   1.724


  14 in total

Review 1.  Novel Approaches for the Management of AL Amyloidosis.

Authors:  Nisha S Joseph; Jonathan L Kaufman
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

2.  Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.

Authors:  Candida Cristina Quarta; Scott D Solomon; Imran Uraizee; Jenna Kruger; Simone Longhi; Marinella Ferlito; Christian Gagliardi; Agnese Milandri; Claudio Rapezzi; Rodney H Falk
Journal:  Circulation       Date:  2014-02-21       Impact factor: 29.690

3.  Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes.

Authors:  S W Dubrey; K Cha; M Skinner; M LaValley; R H Falk
Journal:  Heart       Date:  1997-07       Impact factor: 5.994

4.  Endomyocardial biopsy in 30 patients with primary amyloidosis and suspected cardiac involvement.

Authors:  P A Pellikka; D R Holmes; W D Edwards; R A Nishimura; A J Tajik; R A Kyle
Journal:  Arch Intern Med       Date:  1988-03

5.  Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging: Predicting Survival for Patients With ATTR Cardiac Amyloidosis.

Authors:  Adam Castano; Muhammad Haq; David L Narotsky; Jeff Goldsmith; Richard L Weinberg; Rachelle Morgenstern; Ted Pozniakoff; Frederick L Ruberg; Edward J Miller; John L Berk; Angela Dispenzieri; Martha Grogan; Geoffrey Johnson; Sabahat Bokhari; Mathew S Maurer
Journal:  JAMA Cardiol       Date:  2016-11-01       Impact factor: 14.676

6.  Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis.

Authors:  David Adams; Alejandra Gonzalez-Duarte; William D O'Riordan; Chih-Chao Yang; Mitsuharu Ueda; Arnt V Kristen; Ivailo Tournev; Hartmut H Schmidt; Teresa Coelho; John L Berk; Kon-Ping Lin; Giuseppe Vita; Shahram Attarian; Violaine Planté-Bordeneuve; Michelle M Mezei; Josep M Campistol; Juan Buades; Thomas H Brannagan; Byoung J Kim; Jeeyoung Oh; Yesim Parman; Yoshiki Sekijima; Philip N Hawkins; Scott D Solomon; Michael Polydefkis; Peter J Dyck; Pritesh J Gandhi; Sunita Goyal; Jihong Chen; Andrew L Strahs; Saraswathy V Nochur; Marianne T Sweetser; Pushkal P Garg; Akshay K Vaishnaw; Jared A Gollob; Ole B Suhr
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

7.  Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Authors:  Merrill D Benson; Márcia Waddington-Cruz; John L Berk; Michael Polydefkis; Peter J Dyck; Annabel K Wang; Violaine Planté-Bordeneuve; Fabio A Barroso; Giampaolo Merlini; Laura Obici; Morton Scheinberg; Thomas H Brannagan; William J Litchy; Carol Whelan; Brian M Drachman; David Adams; Stephen B Heitner; Isabel Conceição; Hartmut H Schmidt; Giuseppe Vita; Josep M Campistol; Josep Gamez; Peter D Gorevic; Edward Gane; Amil M Shah; Scott D Solomon; Brett P Monia; Steven G Hughes; T Jesse Kwoh; Bradley W McEvoy; Shiangtung W Jung; Brenda F Baker; Elizabeth J Ackermann; Morie A Gertz; Teresa Coelho
Journal:  N Engl J Med       Date:  2018-07-05       Impact factor: 91.245

8.  Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis.

Authors:  Julien Ternacle; Diane Bodez; Aziz Guellich; Etienne Audureau; Stephane Rappeneau; Pascal Lim; Costin Radu; Soulef Guendouz; Jean-Paul Couetil; Nicole Benhaiem; Luc Hittinger; Jean-Luc Dubois-Randé; Violaine Plante-Bordeneuve; Dania Mohty; Jean-François Deux; Thibaud Damy
Journal:  JACC Cardiovasc Imaging       Date:  2016-01-06

9.  Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis.

Authors:  Julian D Gillmore; Mathew S Maurer; Rodney H Falk; Giampaolo Merlini; Thibaud Damy; Angela Dispenzieri; Ashutosh D Wechalekar; John L Berk; Candida C Quarta; Martha Grogan; Helen J Lachmann; Sabahat Bokhari; Adam Castano; Sharmila Dorbala; Geoff B Johnson; Andor W J M Glaudemans; Tamer Rezk; Marianna Fontana; Giovanni Palladini; Paolo Milani; Pierluigi L Guidalotti; Katarina Flatman; Thirusha Lane; Frederick W Vonberg; Carol J Whelan; James C Moon; Frederick L Ruberg; Edward J Miller; David F Hutt; Bouke P Hazenberg; Claudio Rapezzi; Philip N Hawkins
Journal:  Circulation       Date:  2016-04-22       Impact factor: 29.690

10.  Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis.

Authors:  Marianna Fontana; Silvia Pica; Patricia Reant; Amna Abdel-Gadir; Thomas A Treibel; Sanjay M Banypersad; Viviana Maestrini; William Barcella; Stefania Rosmini; Heerajnarain Bulluck; Rabya H Sayed; Ketna Patel; Shameem Mamhood; Chiara Bucciarelli-Ducci; Carol J Whelan; Anna S Herrey; Helen J Lachmann; Ashutosh D Wechalekar; Charlotte H Manisty; Eric B Schelbert; Peter Kellman; Julian D Gillmore; Philip N Hawkins; James C Moon
Journal:  Circulation       Date:  2015-09-11       Impact factor: 29.690

View more
  2 in total

Review 1.  Myocardial tissue characterisation using echocardiographic deformation imaging.

Authors:  Mohammed A Moharram; Regis R Lamberts; Gillian Whalley; Michael J A Williams; Sean Coffey
Journal:  Cardiovasc Ultrasound       Date:  2019-11-15       Impact factor: 2.062

Review 2.  Diagnosis and treatment of cardiac amyloidosis: position statement of the German Cardiac Society (DGK).

Authors:  A Yilmaz; J Bauersachs; F Bengel; R Büchel; I Kindermann; K Klingel; F Knebel; B Meder; C Morbach; E Nagel; E Schulze-Bahr; F Aus dem Siepen; N Frey
Journal:  Clin Res Cardiol       Date:  2021-01-18       Impact factor: 5.460

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.